Novo Nordisk's Ozempic Under Scrutiny For Potential Increased Risk Of Rare-Eye Disease - Novo Nordisk (NYSE:NVO)

Health Officials Investigating Possible Link Between Ozempic and Eye-Rotting Condition

Ozempic manufacturer Novo Nordisk said patient safety is a priority and “the benefit-risk profile of semaglutide remains unchanged”Ricardo Rubio/Europa Press via GettyHealth officials in Europe are investigating Ozempic and the trendy drug’s possible link to an eye-rotting condition that causes blindness.On Dec. 17, the European Medicines Agency announced that it will review two recently published Danish studies that found that Novo Nordisk’s Oz…

Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). A Scandinavian economic behemoth, Novo Nordisk is the highest-valued company in Europe at over $500 billion, which exceeds Denmark’s entire GDP.  Ironically, Ozempic and Wegovy, as with many of Novo Nordisk’s other products, …

Novo Nordisk's Ozempic Under Scrutiny For Potential Increased Risk Of Rare-Eye Disease - Novo Nordisk (NYSE:NVO)

Two new studies from the University of Southern Denmark suggest that Ozempic, a diabetes medication from Novo Nordisk A/S (NYSE:NVO), may increase the risk of developing a rare eye condition. What Happened: Results from a study conducted in Denmark and Norway revealed a potential link between the use of semaglutide for type 2 diabetes and an increased risk of non-arteritic anterior ischemic optic neuropathy (NAION). The Danish Medicines Agency p…

Two new studies to be published by researchers at the University of Southern Denmark show that the risk of developing this condition, which can go as far as blindness, is doubled in diabetic patients treated with this medication. The side effect is rare, but should be considered if confirmed.

Healthy Returns: Novo Nordisk's Ozempic faces scrutiny over potential link to rare eye condition

A vision-threatening eye condition may be linked to Ozempic. Meanwhile, Nearly 80% of doctors are using telemedicine weekly, a new Doximity report finds.

EU reportedly reviewing link between Ozempic, rare eye disease

European drug regulators are reportedly reviewing research that links Novo Nordisk’s blockbuster diabetes injection Ozempic to a rare eye disorder. After the release of two independent studies from the University of Southern Denmark that suggested Type 2 diabetes patients who are treated with Ozempic have an increased risk of developing damage to the optic nerve of the eye, the European Union decided to investigate, according to Reuters. The mov…